Johann S. de Bono, MB ChB, FRCP, MSc, PhD,
The Institute of Cancer Research, The Royal Marsden
This presentation will focus on the improved understanding of castration-resistant prostate cancer and the delivery of precision medicine for this disease. Recent developments with abiraterone, enzalutamide, cabazitaxel, and radium-223 will be discussed. Data on novel agents including AKT, p110b, and poly(ADP-ribose) polymerase inhibitors and cabozantinib will also be discussed. The study of exome and transcriptome data in early clinical trials for advanced prostate cancer to drive the pharmacological audit trail will also be presented.
